Second-line therapy of small-cell lung cancer: Topotecan compared to a combination treatment with adriamycin, cyclophosphamide and vincristine (ACO) - A single center experience

Journal of Cancer

Volumn 6, Issue 11, 2015, Pages 1148-1154

  Hagmann, Raphael ^a   Hess, Viviane ^a   Zippelius, Alfred ^a   Rothschild, Sacha I ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

ACO; Chemotherapy; Second line therapy; Small cell lung cancer; Topotecan

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKULL IRRADIATION; SMALL CELL LUNG CANCER; SYSTEMIC THERAPY; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84947745907     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13080     Document Type: Article

References (24)

1. Herbst RS, Heymach J V, Lippman SM: Lung cancer. N Engl J Med 2008 Sep 25;359:1367-80.
2. Stupp R, Monnerat C, Turrisi AT, Perry MC, Leyvraz S: Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004 Jul;45:105-17.
3. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 2000 Mar;18:106-15.
4. Clark R, Ihde DC: Small-cell lung cancer: treatment progress and prospects. Oncology (Williston Park) 1998 May;12:647-58; discussion 661-3.
5. Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 2012 May;7:866-72.
6. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Dr. J Clin Oncol 1997 May;15:2090-6.
7. Morabito A, Carillio G, Daniele G, Piccirillo MC, Montanino A, Costanzo R, et al. Treatment of small cell lung cancer. Crit Rev Oncol Hematol 2014 Sep;91:257-70.
8. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999 Feb;17:658-67.
9. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007 Aug;2:706-14.
10. Stahel R, Ginsberg R, Havemann K, Al E: Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989;5:119-126.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 Feb 2;92:205-16.
12. Cheng S, Evans WK, Stys-Norman D, Shepherd FA: Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007 Apr;2:348-54.
13. Fiegl M, Pircher A, Waldthaler C, Gamerith G, Kocher F, Pall G, et al. Small steps of improvement in small-cell lung cancer (SCLC) within two decades: a comprehensive analysis of 484 patients. Lung Cancer 2014 May;84:168-74.
14. Shipley D, Hainsworth J, Spigel D, Barton J, Switzer A, et al. Topotecan: Weekly Intravenous schedule similar to standard 5-day IV schedule as Second-Line therapy for Relapsed Small Cell Lung Cancer: A Minnie Pearl Cancer Research Net-work Phase II trial. ASCO Annu Meet Proc part I 2006;24:abstract 7083.
15. Shah C, Ready N, Perry M, Kirshner J, Gajra A, Neuman N, et al. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 2007 Jul;57:84-8.
16. O'Brien MER, Ciuleanu T-E, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer. J Clin Oncol 2006 Nov 6;24:5441-5447.
17. Eckardt JR, von Pawel J, Pujol J-L, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007 May 20;25:2086-92.
18. Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W: Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987 Sep;23:1409-11.
19. Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A: Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987 Nov;23:1697-9.
20. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013 Jan;24:75-83.
21. Ott PA, Elez Fernandez ME, Hiret S, Kim D-W, Moss RA, Winser T, et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol 2015;33(suppl): abstr7502.
22. Antonia SJ, Bendell JC, Taylor MH, Calvo E, Jaeger D, De Braud FG, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol 2015;33(suppl): abstr7503.
23. The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979 Nov 3;121:1193-254.
24. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992 Nov 4;268:2420-5.